SciLifeLab Industry case: Rarity Bioscience enables precision medicine with superRCA technique

SciLifeLab case

Industry case by SciLifeLab: Rarity Bioscience and SciLifeLab are collaborating to advance superRCA, a powerful tool for nucleic acid detection. The technique, initially a Technology Development Project at SciLifeLab, improves existing genetic technologies to enhance precision in identifying cancer mutations. Using expertise and equipment available at SciLifeLab Clinical Genomics, Rarity Bioscience can retrospectively test superRCA, a […]

New perspective article on Liquid Biopsy using superRCA

Journal of Internal Medicine_abstract_managing leukemia patients via liquid biopsy and superRCA_RArity

New perspective article on Liquid Biopsy using superRCA, from Uppsala University and Karolinska Institute: This perspective article compares existing techniques and the benefits and drawbacks of various types of assays for different applications, and their utility for diagnosis and monitoring. The authors discuss molecular methods for monitoring malignancies, particularly leukemias, and compare them to the […]

New chairperson of the board brings cutting-edge expertise

Per Matsson_Rarity

Per Matsson, an esteemed biotechnology leader, has been appointed as the new chairman of the Board at Rarity Bioscience. His appointment signifies Rarity Bioscience’s commitment to strong leadership and innovation in the biotech sector. Per Matsson is also one of the Co-founders of Rarity Bioscience. Per Matsson has over 30 years of life science experience, […]

New poster presented at International Symposium on Minimal Residual Cancer conference

ISMRC poster 2023

CEO Linus Bosaeus, CTO Lei Chen and Dir. BD Alexander Kele attended the ISMRC (International Symposium on Minimal Residual Cancer) Conference in Hamburg, germany, 2023, to discuss topics such as precision diagnostics, liquid biopsies and treatment monitoring and present a new poster. The poster demonstrates initial data from a pilot study looking at the utility of cfDNA mutation […]

MRD poster presented at international AML conference

2023 Munich AML conference poster_Rarity_cut

CEO Linus Bosaeus and co-founder and CTO Dr. Lei Chen attended the AML Conference in Munich, Germany 2023, to engage and discuss the main topics of this year such as novel target therapies and markers for Diagnosis and Prognosis. Linus Bosaeus and Lei Chen are there Monday til Wednesday and present poster #79, demonstrating positive […]

New assay available in our product portfolio


Using the superRCA technology, you can essentially detect any known sequence of interest using target specific ligation templates and padlock probes. The assay work on purified DNA coming from various types of samples, including cfDNA from liquid biopsies. Targets may be hotspot mutations, private driver mutations, or simply any sequence of interest. We now have […]

Collaboration project for better health is progressing strongly


Last spring, Rarity was awarded a grant from Swelife and Medtech4Health. The idea is to study superRCA for precision diagnostics and relapse detection for Acute Myeloid Leukemia and Myelodysplastic syndrome – ultimately improving treatment outcome, reducing patient burden and cost. Part of the project aims to benchmark superRCA against ddPCR and investigate to what extent […]

Novalis Biotech invests in Rarity Bioscience’s
ultra sensitive genomics technology

Wim Van Criekinge, Co-Founder and Managing Director at Novalis_Linus Bosaeus, CEO at Rarity Bioscience

To further accelerate growth, Rarity Bioscience announces today a new strategicinvestment from Belgium based Novalis Biotech. The investment is facilitated as anoversubscription of the recent round closed in November 2022. Apart from previousowner, that round also included Wallenberg Investments through Navigare Venture,now bringing the total investment round to €3M. Novalis Biotech (Ghent, Belgium) is an […]

Rarity Bioscience raises €2,5M in seed funding to improve cancer care

Linus Bosaeus, CEO Rarity Bioscience

With the aim to improve cancer diagnostics, Rarity Bioscience has raised €2,5 million to expand operations and product development within precision diagnostics and liquid biopsy. The seed round was led by founders and joined by new investor, Navigare Ventures, owned by Wallenberg Investments AB. This investment round has come after a successful first year establishing […]

Free analysis for cancer researchers

Movember cancer

During November, Rarity Bioscience offer free analysis of liquid biopsy samples for cancer research. Movember is a month-long event to raise awareness of men’s health issues, and we want to do our part. Movember aims to increase early cancer detection, diagnosis, effective treatments and ultimately reduce the number of preventable deaths. At Rarity Bioscience, our vision […]